Chitsulo L, Engels D, Montresor A, Savioli L, 2000. The global status of schistosomiasis and its control. Acta Trop 77: 41–51.
King CH, Dickman K, Tisch D, 2005. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability related outcomes in endemic schistosomiasis. Lancet 365: 1561–1569.
Gryseels B, Polman K, Clerinx J, Kestens L, 2006. Human schistosomiasis. Lancet 368: 1106–1118.
Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J, 2006. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6: 411–425.
Murray CJ et al. 2013. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet 380: 2197–2223.
World Health Organization, 1985. The control of schistosomiasis: report of a WHO Expert Committee. World Health Organ Tech Rep Ser 728: 1–113.
WHO, 2002. Prevention and Control of schistosomiasis and Soil-Transmitted helminthiasis: Report of a WHO Expert Committee. Report No.: 912. Technical Report Series. Geneva, Switzerland: World Health Organization.
WHO, 2006. Preventive Chemotherapy in Human helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions: A Manual for Health Professionals and Programme Managers. Geneva, Switzerland: World Health Organization.
Hatz CF, 2001. The use of ultrasound in schistosomiasis. Adv Parasitol 48: 225–284.
Akpata R, Neumayr A, Holtfreter MC, Krantz I, Singh DD, Mota R, Walter S, Hatz C, Richter J, 2015. The WHO ultrasonography protocol for assessing morbidity due to Schistosoma haematobium. Acceptance and evolution over 14 years. Systematic review. Parasitol Res 114: 1279–1289.
Brouwer KC, Ndhlovu PD, Wagatsuma Y, Munatsi A, Shiff CJ, 2003. Epidemiological assessment of Schistosoma haematobium-induced kidney and bladder pathology in rural Zimbabwe. Acta Trop 85: 339–347.
Kahama AI, Vennervald BJ, Kombe Y, Kihara RW, Ndzovu M, Mungai P, Ouma JH, 1999. Parameters associated with Schistosoma haematobium infection before and after chemotherapy in school children from two villages in the coast province of Kenya. Trop Med Int Health 4: 335–340.
Andrade G, Bertsch DJ, Gazzinelli A, King CH, 2017. Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: a systematic review and meta-analysis. PLoS Negl Trop Dis 11: e0005372.
Shen Y et al. 2017. Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on functional morbidities from schistosomiasis in four African countries. BMC Infect Dis 17: 652.
Doehring E, Ehrich JH, Bremer HJ, 1986. Reversibility of urinary tract abnormalities due to Schistosoma haematobium infection. Kidney Int 30: 582–585.
Bocanegra C et al. 2015. Epidemiology of schistosomiasis and usefulness of indirect diagnostic tests in school-age children in Cubal, central Angola. PLoS Negl Trop Dis 9: e0004055.
Bocanegra García C et al. 2018. Ultrasound findings and associated factors to morbidity in Schistosoma haematobium infection in a highly endemic setting. Trop Med Int Health 23: 221–228.
Richter J, Hatz C, Campagne G, Bergquist N, Jenkins J, 2000. Ultrasound in schistosomiasis: A Practical Guide to the Standardized Use of Ultrasonography for the Assessment of schistosomiasis-Related Morbidity. Geneva, Switzerland: World Health Organization.
Magak P, Chang-Cojulun A, Kadzo H, Ireri E, Muchiri E, Kitron U, King CH, 2015. Case-control study of posttreatment regression of urinary tract morbidity among adults in Schistosoma haematobium-endemic communities in Kwale County, Kenya. Am J Trop Med Hyg 93: 371–376.
DeAlegria MLAR et al. 2017. Prevalence of Strongyloides stercoralis and other intestinal parasite infections in school children in a rural area of Angola: a cross-sectional study. Am J Trop Med Hyg 97: 1226–1231.
Vale N, Gouveia MJ, Rinaldi G, Brindley PJ, Gärtner F, Correia da Costa JM, 2017. Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrob Agents Chemother 61: pii:e02582–16.
Senghor B, Diaw OT, Doucoure S, Seye M, Diallo A, Talla I, Bâ CT, Sokhna C, 2016. Impact of annual praziquantel treatment on urogenital schistosomiasis in a seasonal transmission focus in central Senegal. PLoS Negl Trop Dis 10: e0004557.
Zwang J, Olliaro PL, 2014. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis 8: e3286.
Nalugwa A, Nuwaha F, Tukahebwa EM, Olsen A, 2015. Single versus double dose praziquantel comparison on efficacy and Schistosoma mansoni re-infection in preschool-age children in Uganda: a randomized controlled trial. PLoS Negl Trop Dis 9: e0003796.
Garba A et al. 2013. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger. Acta Trop 128: 334–344.
Ahmed AM, Abbas H, Mansour FA, Gasim GI, Adam I, 2012. Schistosoma haematobium infections among schoolchildren in central Sudan one year after treatment with praziquantel. Parasit Vectors 5: 108.
Olliaro PL et al. 2011. A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Negl Trop Dis 5: e1165.
Russell Stothard J, Sousa-Figueiredo JC, Simba Khamis I, Garba A, Rollinson D, 2009. Urinary schistosomiasis-associated morbidity in school children detected with urine albumin to creatinin ratio (UACR) reagent strips. J Pediatr Urol 5: 287–291.
Murare HM, Taylor P, 1987. Haematuria and proteinuria during Schistosoma haematobium infection: relationship to intensity of infection and the value of chemical reagent strips for pre and post-treatment diagnosis. Trans R Soc Trop Med Hyg 81: 426–430.
Honeycutt J, Hammam O, Fu CL, Hsieh MH, 2014. Controversies and challenges in research on urogenital schistosomiasis-associated bladder cancer. Trends Parasitol 30: 324–332.
Danso-Appiah A, Utzinger J, Liu J, Olliaro P, 2008. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev 200: CD000053.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||497||127||4|
Urinary schistosomiasis causes damage to the urological system. Ultrasound is a method that detects the burden of secondary disease, individually and in epidemiological studies. In this study, the Schistosoma haematobium–associated urinary tract pathology is analyzed before and after treatment in a short period of time. Seventy children who had previously participated in an epidemiological study on schistosomiasis in the city of Cubal, Angola, and had also performed urinary ultrasound between August 2013 and February 2014 were cited 6–8 months later to assess the possible reinfection and repeat new urinary ultrasound, analyzing changes at the level of urinary pathology. The presence of hematuria and proteinuria was also analyzed. Of the 70 children analyzed, 29 (41.4%) were girls, with an average age of 10.4 years (standard deviation 2.3). Fifty-three (75.7%) had an improvement in their bladder and/or kidney scores, whereas 12 (17.1%) had no change and five (7.1%) had progression of the disease. None of the parameters analyzed completely disappeared. After one single course of treatment with praziquantel, all the analyzed parameters showed regression. Improvement was greater in the urinary bladder than in the upper urinary tract, though these lesions also reversed; the reversion of all parameters was greater among children older than 10 years old than the younger ones. Proteinuria was the parameter with a smaller reduction. Ultrasound should be a usual tool for diagnosis and follow-up in urinary schistosomiasis, particularly in children; more accurate recommendations about follow-up in the case of children whose lesions do not reverse should be established.
Authors’ addresses: Cristina Bocanegra, Departament de Medicina, Tropical Medicine and International Health Unit Vall d’Hebron Drassanes, PROSICS Barcelona, Universitat Autonoma de Barcelona, Barcelona, Spain, E-mail: email@example.com. Zeferino Pintar, Department of Radiology, Hospital Nossa Senhora da Paz, Cubal, Angola, E-mail: firstname.lastname@example.org. Jacobo Mendioroz, Territorial Health Management of Central Catalonia, Support Research Unit, Barcelona, Spain, E-mail: email@example.com. Xavier Serres, Department of Radiology, University Hospital Vall d’Hebron, Barcelona, Spain, E-mail: firstname.lastname@example.org. Sara Gallego and Nicolau Sikaleta, Department of Paediatrics, Hospital Nossa Senhora da Paz, Cubal, Angola, E-mails: email@example.com and firstname.lastname@example.org. Arlette Nindia, Department of Microbiology, Hospital Nossa Senhora da Paz, Cubal, Angola, E-mail: email@example.com. Maria Luisa Aznar, Department of Infectious Diseases, Hospital Nossa Senhora da Paz, Cubal, Angola, and Tropical Medicine and International Health Vall d’Hebron Drassanes, PROSICS Barcelona, Barcelona, Spain, E-mail: firstname.lastname@example.org. Antoni Soriano-Arandes, Department of Paediatrics, Tropical Medicine and International Health Vall d’Hebron Drassanes, PROSICS Barcelona, Barcelona, Spain, E-mail: email@example.com. Fernando Salvador, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, Barcelona, Spain, E-mail: firstname.lastname@example.org. Eva Gil, Department of Internal Medicine, Hospital Nossa Senhora da Paz, Cubal, Angola, E-mail: email@example.com. Milagros Moreno, Department of Infectious Diseases, Hospital Nossa Senhora da Paz, Cubal, Angola, E-mail: firstname.lastname@example.org. Israel Molina, Department of Infectious Diseases, Hospital Vall d’Hebron, PROSICS Barcelona, Barcelona, Spain, E-mail: email@example.com.